Golimumab & PsA: Reduced Corticosteroid Use
Psoriatic Arthritis Treatment: Golimumab,Methotrexate,and Corticosteroids – A Deep Dive
This analysis summarizes findings from a study investigating the efficacy of adding golimumab to a methotrexate and corticosteroid regimen for early psoriatic arthritis (PsA). The study, lead by Dr. Gabriele De Marco, aimed to address treatment needs and potential inequities in access to advanced therapies.
Key Takeaways:
Reduced Corticosteroid Use: Adding golimumab to methotrexate and corticosteroids substantially reduced the need for rescue corticosteroids.
Maintained Efficacy: The combination therapy maintained treatment efficacy in patients with early PsA.
Pragmatic Approach: The study highlights the need for pragmatic and effective treatment strategies, particularly given global health inequities limiting access to advanced therapies.
Patient-Centered Research: Identifying optimal treatment strategies for PsA is a top research priority for patients and caregivers.
Study Details:
Design: Double-blind, randomized, placebo-controlled, parallel-group, single-center study.
Dates: November 3, 2015 – January 26, 2022.
Participants: 84 adults with treatment-naïve active PsA.
Randomization: 1:1 ratio – Golimumab + Methotrexate (n=43) vs. Placebo + Methotrexate (n=41).
Stratification: Based on the number of involved peripheral joints at baseline.Participant Demographics:
| Characteristic | Value |
|—|—|
| Total Participants | 84 |
| Male (%) | 55% (n=46) |
| Female (%) | 45% (n=38) |
| Mean Age (Years) | 42.5 (SD 12.4) |
| White (%) | 73% (n=61) |
| Other Ethnicities (%) | 8% (n=7) |
Treatment Protocol:
- Baseline: All participants received a single 120mg intramuscular methylprednisolone dose.
- Methotrexate: Weekly methotrexate, increasing to 25mg within 28 days.
- Golimumab/Placebo: subcutaneous injections every 4 weeks.
- Rescue Corticosteroids: Permitted once up to week 24, totaling up to 240mg exposure.
Primary Endpoint:
difference in mean Psoriatic Arthritis Disease Activity Score (PASDAS) at week 24. (Further results regarding PASDAS were not provided in the text.)
Context & Meaning:
Current treatment guidelines recommend a step-up approach, starting with methotrexate or other conventional synthetic DMARDs before considering biological or targeted synthetic DMARDs. However, access to these advanced therapies remains a challenge globally, even with the availability of biosimilars. This study provides evidence supporting the potential benefits of early combination therapy to optimize treatment outcomes and potentially reduce reliance on long-term corticosteroid use.
– drjenniferchen